Loading clinical trials...

The Effect of Foot Massage With Roles on Cancer Patients | Clinical Trials | Clareo Health

ENROLLING_BY_INVITATIONNA

The Effect of Foot Massage With Roles on Cancer Patients

Roles in the Management of Treatment-Induced Peripheral Neuropathy in Cancer Patients Receiving Taxane-Based Chemotherapy and the Effect of Foot Massage on Neuropathy and Quality of Life: A Randomized Controlled Study

NCT06376357•Selcuk University

View on ClinicalTrials.gov

Summary

It was aimed to examine the roles in the management of treatment-related peripheral neuropathy in cancer patients receiving taxane-based chemotherapy and the effect of foot massage on neuropathy and quality of life.

Detailed Description

Intervention Phase of the Research; 1. Patient information about neuropathy caused by chemotherapy and its management, 2. Teaching the role application to the patient, 3. Application process 4. It will be carried out in 4 steps, including patient monitoring via telemonitoring.

Eligibility

Age

18 - 65 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Being registered in the medical oncology outpatient clinic of Selçuk University Faculty of Medicine Hospital
•Completed standard taxane-based chemotherapy treatment protocol for breast and ovarian cancer
•Karnofsky Performance Scale being 80 and above (Performance scale of cancer patients)
•Being 18 years or older
•Having received at least 3 cycles of taxane-based treatment
•Presence of grade 2 or higher peripheral neuropathy
•Being conscious and cooperative
•Verbal and written approval to participate in the study after an explanation about the study is made.

Exclusion Criteria

•Previous skin sensitivity on hands and feet
•Refused to participate in the study after making a statement about the study
•Development of peripheral neuropathy due to reasons other than chemotherapy \[tumor compression, nutritional disorders, infections or major systemic disease (diabetes mellitus, etc.)\]
•Bone, spine metastasis or malignancy
•Having mental and psychic problems that would prevent him from taking part in the research.

Locations (1)

ülkü Saygili Düzova

Selçuklu, Konya, Turkey (Türkiye)

Key Dates

Start Date

April 27, 2024

Primary Completion Date

June 15, 2024

Completion Date

July 30, 2024

Last Updated

April 19, 2024

Enrollment

ESTIMATED participants

Conditions

Breast NeoplasmsOver CancerFoot Massage

Interventions

Foot Massage with roller

OTHER

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT07191730

CardiotoxicityHeart Failure+2 more

View study

RECRUITINGPHASE3

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176

Breast Neoplasms

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 19, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Effect of Foot Massage With Roles on Cancer Patients

Inclusion Criteria

Exclusion Criteria

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Evaluation of Clinical Efficacy of Augmented Reality (AR)-Based Breast Cancer Medical Imaging Solution (SKIA-Breast) Localization Method in Breast Cancer Patients

Dissemination of BREASTChoice AIM1-B

Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B